Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
175
NCT01060475
Safety and Tolerability of LIM-0705 in Healthy Male Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2010
Completion: Jun 30, 2010
NCT01093677
Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
Start: Mar 31, 2010
Completion: Jul 31, 2010
NCT01364155
Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR
Phase: Phase 2
Start: May 31, 2011
Completion: Aug 31, 2011
NCT02223312
Therapy for Progressive and/or Refractory Hematologic Malignancies
Phase: Phase 1/2
Start: Jul 28, 2017
Completion: Jan 31, 2019
NCT02224599
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Completion: Aug 30, 2018
NCT02705703
Consolidation Therapy in Patients With Metastatic Solid Malignancies
NCT02709993
Consolidation Therapy in Patients With Hematologic Malignancies
Completion: Oct 31, 2020
NCT06069570
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Start: Nov 7, 2023
Completion: Oct 31, 2026